Molex Acquires Vectura Group Limited to Strengthen Drug Delivery Capabilities in Inhalation Solutions
Molex, the parent company of Phillips Medisize, announced its affiliate, Molex Asia Holdings LTD., has signed an agreement to acquire Vectura Group Limited from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International (NYSE: PM).
Hudson, WI, September 17, 2024 – Molex, the parent company of Phillips Medisize, announced its affiliate, Molex Asia Holdings LTD., has signed an agreement to acquire Vectura Group Limited from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International (NYSE: PM). This acquisition solidifies Molex’s commitment to enhancing its pharmaceutical drug delivery, in vitro diagnostic, and medtech capabilities. Vectura, headquartered in Chippenham, UK, is a recognized leader in inhalation drug device design and formulation. The company specializes in dry powder inhalers (DPI), pressurized metered dose inhalers (pMDI), nasal products, and nebulizers for small molecules, biologics, and complex combinations. Vectura also offers regulatory, technical transfer, and clinical trial support services.
By integrating Vectura’s expertise, Phillips Medisize will expand its portfolio, providing advanced inhalation combination drug devices to pharmaceutical customers. Paul Chaffin, President of Phillips Medisize, expressed enthusiasm for the acquisition: “Combining the strengths of Phillips Medisize and Vectura will enhance our ability to deliver innovative solutions for chronic and acute diseases like asthma and COPD. Our global reach and engineering expertise uniquely position us to support Vectura’s development of groundbreaking products.”
Phillips Medisize employs over 6,000 professionals across 29 global sites. The company designs, engineers, and manufactures healthcare and pharmaceutical products, leveraging Molex’s specialty electronics and optical fiber expertise. Molex CEO Joe Nelligan highlighted the strategic importance of the acquisition: “The addition of Vectura underscores our commitment to building industry-leading medical capabilities. It positions us to meet the growing demand for inhalation therapies and combination products.” The transaction, expected to close by the end of 2024 pending regulatory approvals, promises to create significant growth opportunities while improving patient outcomes worldwide.
